This bill establishes a regulatory framework for the registration and oversight of hemp-derived cannabinoids in New Jersey, particularly addressing concerns over psychoactive products like Delta-8-THC. The Cannabis Regulatory Commission is designated as the authority responsible for the registration, testing, and labeling of these products, ensuring they comply with safety standards. The legislation introduces new definitions related to cannabinoids and expands the commission's powers to include the regulation of hemp-derived products alongside traditional cannabis. It also mandates the creation of rules for registration, testing, and sales, while establishing age restrictions and specific labeling requirements to protect consumers.

Additionally, the bill amends existing laws to include testing requirements for hemp-derived cannabinoid products, stipulating that they must be tested by licensed laboratories that adhere to strict protocols. It introduces a labor peace agreement requirement for these laboratories and outlines the process for conducting criminal history background checks for applicants in the medical cannabis testing field. Retailers selling hemp-derived products prior to the bill's enactment are given a one-year compliance period. Overall, the legislation aims to ensure that hemp-derived cannabinoid products are safely produced, sold, and tested, without banning them outright.

Statutes affected:
Introduced: 24:6I-34, 24:6I-17, 24:6I-18